Cathie Wood’s ARK sells AMD stock, buys Roblox and Intellia

ARK reported a net risk-on shift on May 1, 2026, buying 306,924 shares of Roblox for $16.96 million and 140,963 shares of Intellia Therapeutics for $1.90 million. The firm also sold 36,133 shares of AMD for $12.81 million and 123,192 shares of Twist Bioscience for $7.20 million, indicating ongoing portfolio rotation out of established tech names. The trades are notable for individual stocks but are unlikely to drive broader market action.

Analysis

The important signal is not the headline flow itself but the changing factor mix: ARK is adding beta to secular growth with RBLX and NTLA while monetizing more mature, high-multiple software/semis exposure in AMD and TWST. That usually matters most when the market is rewarding narrative durability over near-term fundamentals; in this regime, the incremental bid can keep winners running for days, but the more interesting effect is rotation pressure on adjacent names with similar factor exposure that are not receiving the same sponsorship.

RBLX looks like the cleanest beneficiary because it sits at the intersection of consumer engagement, platform monetization, and optionality around creator economics. If the flow persists, the second-order winner is not just RBLX but the broader “gaming/interactive media” basket, where relative performance can improve even without fresh fundamentals. By contrast, AMD and TWST can underperform on margin compression fears or valuation reset if this is interpreted as informed de-risking rather than simple rebalancing, especially over a 2-6 week horizon.

NTLA is a more asymmetric expression: continued accumulation in a small-cap biotech can create a self-reinforcing move if other biotech holders infer improving conviction, but the stock remains highly sensitive to one trial/financing headline. That makes the trade more about timing than conviction — flows can support it for several sessions, but the reversal risk is high if broader biotech risk appetite fades. The contrarian read is that the market may be overestimating ARK’s ability to move fundamentals; these trades are better seen as a sentiment accelerator than a durable valuation anchor.

The non-obvious setup is a relative-value short against the names being trimmed rather than outright bearish single-name bets. If the market continues to reward AI-adjacent or innovation-heavy exposures, the crowded longs can stay crowded, but the losers here have weaker flow support and are more exposed to disappointment once the next earnings window opens.

Key Decisions for Investors

• Long RBLX vs short TWST in a 3-6 week pair trade: favor the higher-quality flow beneficiary over the name facing persistent distribution; target 8-12% relative outperformance, stop if TWST reclaims momentum on biotech-wide strength.
• Short AMD on a 2-4 week horizon only as a tactical trade, not a structural call: use tight risk controls because semis can re-rate quickly, but flow pressure suggests 5-8% downside before the next catalyst if the de-risking narrative persists.
• Buy NTLA on weakness, but only with a catalyst window of 1-3 months: the setup is flow-supported and asymmetric, yet position size should be modest given binary trial/financing risk; aim for 15-20% upside versus 10% downside.
• Use call spreads on RBLX for a 1-2 month tactical long: upside is supported by momentum and positioning, while defined-risk structures protect against abrupt reversal if the market fades ARK-related enthusiasm.
• Avoid chasing TWST here; instead wait for a post-flow bounce to fade into strength over the next 5-10 trading days, since repeated selling into liquidity often pressures the stock until a new fundamental catalyst appears.